GSK Bio
NEWS
The two companies joined their consumer health businesses in order to give the parent companies more maneuverability to focus on the pharmaceuticals.
Emma Walmsley, chief executive officer of GlaxoSmithKline, is predicting a good year for her company, with the potential of six regulatory approvals in the United States.
Turbine, a simulation-first drug discovery company, announced the formation of its Scientific Advisory Board with the appointments of Dr. Annalisa Jenkins, Dr. Mihriban Tuna, and Dr. Alan Barge.
A Chinese scientist living abroad who has been accused of accepting stolen intellectual property to benefit a pharma startup in China has been extradited to the United States.
According to an analysis conducted on Jan. 1, more than 250 drugs manufactured by different companies saw price increases.
Zelluna Immunotherapy announces the appointment of Namir Hassan as chief executive officer.
A comprehensive map of genes necessary for cancer survival is one step closer, following the validation of the two largest CRISPR-Cas9 genetic screens in 725 cancer models, across 25 different cancer types.
The FDA issued a Complete Response Letter for its combination treatment of cabotegravir and rilpivirine.
Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look.
JOBS
IN THE PRESS